期刊文献+

孟鲁司特联合糠酸氟替卡松对支气管哮喘患儿的效果 被引量:6

Effect of montelukast combined with fluticasone furoate in children with bronchial asthma
下载PDF
导出
摘要 目的研究孟鲁司特联合糠酸氟替卡松对支气管哮喘患儿血清微小核糖核酸-21(miRNA-21)、微小核糖核酸-26a(miRNA-26a)相对表达量的影响以及肺功能、气道重塑情况等指标的影响。方法对照组患儿通过常规方法治疗支气管哮喘,试验组患儿在对照组治疗的基础上应用孟鲁司特联合糠酸氟替卡松进行治疗,连续治疗12周后,观察患儿的治疗效果、miRNA-21及miRNA-26a水平、气道重塑指标以及不良反应发生率。结果试验组患儿经治疗后症状改善以及肺功能恢复情况、炎症因子等各指标下降程度明显优于对照组,差异有统计学意义(P<0.05)。试验组患儿治疗后miRNA-21、miRNA-26a相对表达量、网状基底膜厚度以及成纤维细胞数量下降程度显著高于对照组患儿(P<0.05)。2组患儿的不良反应发生率比较差异无统计学意义(P>0.05)。结论孟鲁司特联合糠酸氟替卡松治疗支气管哮喘患儿能有效降低患儿血清miRNA-26a和miRNA-21的相对表达量,避免气道重塑的发生,同时能较好地抑制哮喘症状。 Objective To study the effect of montelukast combined with fluticasone furoate on the relative expression of micronucleic acid-21(miRNA-21)and micronucleic acid-26a(miRNA-26a),and the change of lung function and airway remodeling in children with asthma.Methods Children in the control group were treated by conventional methods,while the children in the experimental group were treated by montelukast combined with fluticasone furoate on the conventional basis.12 weeks after treatment,the treatment effect of children,serum miRNA-21 and miRNA-26a level,airway remodeling index and incidence of adverse reactions were observed.Results After treatment,the symptoms of children in the experimental group were improved,lung function recove-ry,inflammatory factors and other indicators decreased significantly,better than those in the control group,and the difference was statistically significant(P<0.05).The relative expression levels of miRNA-21 and miRNA-26a,the thickness of reticular basement membrane and the number of fibroblasts in the experimental group were significantly higher than those in the control group after treatment(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion The combination of montelukast and fluticasone furoate in the treatment of children with bronchial asthma can effectively reduce the relative expression levels of serum miRNA-26a and miRNA-21 in children with bronchial asthma,avoid the occurrence of airway remodeling,and well inhibit the symptoms of asthma,which has the significance of practical promotion.
作者 沙宁 王艳 SHA Ning;WANG Yan(Department of Pediatrics,Haian People′s Hospital,Haian 226600,China;Department of Pediatrics,Xuzhou Central Hospital,Jiangsu Province,Xuzhou 221009,China)
出处 《西北药学杂志》 CAS 2021年第2期283-287,共5页 Northwest Pharmaceutical Journal
基金 2017年江苏省重点研发计划(社会发展)项目(编号:BE2017639)。
关键词 孟鲁司特 糠酸氟替卡松 小儿支气管哮喘 微小核糖核酸-21(miRNA-21) 微小核糖核酸-26a(miRNA-26a) montelukast fluticasone furoate bronchial asthma in children micronucleic acid-21(miRNA-21) micronucleic acid-26a(miRNA-26a)
  • 相关文献

参考文献22

二级参考文献223

  • 1焦琳,刘月.用布地奈德混悬液雾化吸入治疗小儿支气管哮喘的疗效观察[J].求医问药(下半月),2013(8):273-274. 被引量:5
  • 2姜之炎,吴玉晶.小儿敷贴粉对哮喘大鼠气道影响的实验研究[J].上海中医药大学学报,2005,19(3):55-57. 被引量:11
  • 3邱明义,曹远礼,俞良栋,李波.附子汤、桂枝附子汤、芍药甘草汤镇痛抗炎作用比较研究[J].中国实验方剂学杂志,1996,2(4):47-49. 被引量:30
  • 4曹艳,旺建伟,段淑香,王红.芍药甘草汤临床及药理研究近况[J].中医药信息,2006,23(3):41-43. 被引量:33
  • 5Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal struc- ture of the novel enhanced-affinity glucocorticoid agonist flutica- sone furoate in the glucocorticoid receptor-ligand binding domain [J]. J Med Chem,2008,51 (12):3349 -52.
  • 6Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to flutieasone propionate in human respiratory cells[J].Eur J Pharmaeol. 2011 ;670( 1 ) :244 -51.
  • 7Zhang N, Van Crombruggen K, Holtappels G, et al. Suppression of eytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo[ J]. PLoS One. 2014 ;9(4) :e93754.
  • 8Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glueoeortieoid flutieasone furoate in vitro and in an in vivo model of respiratory inflammatory disease [ J ]. Am J Physiol Lung Cell Mol Physiol. 2007 ;293 (3) : 1.660 - 7.
  • 9Cazzola M, Page CP, Calzetta L, et al. Pharmacology and thera- peutics of bronchodilators [ J ]. Pharmacol Rev. 2012 ;64 ( 3 ) : 450 -504.
  • 10Slack R J, Barrett V J, Morrison VS, et al. In vitro pharmacologi- cal characterization of vilanterol, a novel long-acting b 2-adreno- ceptor agonist with 24-hour duration of action [ J ]. J Pharmacol Exp Ther. 2013;344(1) :218 -30.

共引文献316

同被引文献108

引证文献6

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部